Anti-Trem2 anti­body treat­ment as a pos­sible ther­apy to treat Alzheimer’s disease.

Mod­u­lat­ing Trem2 sig­nal­ing through Trem2 ant­ag­on­istic anti­bod­ies can alter microglia func­tion and cause dis­ease-rel­ev­ant changes in Alzheimer’s disease.

Enhan­cing pro­tect­ive microglial activ­it­ies with a dual func­tion TREM2 anti­body to the stalk region.

Schlep­ckow K, Mon­roe KM, Klein­ber­ger G, Can­tuti-Castel­vetri L, Par­hizkar S, Xia D, Willem M, Werner G, Pettkus N, Brun­ner B, Sülzen A, Nuscher B, Hampel H, Xiang X, Feed­erle R, Tahirovic S, Park JI, Pro­rok R, Mahon C, Liang CC, Shi J, Kim DJ, Sabel­ström H, Huang F, Di Paolo G, Simons M, Lew­cock JW, Haass C. EMBO Mol Med. 2020 Apr 7;12(4):e11227. doi: 10.15252/emmm.201911227. Epub 2020 Mar 10. PMID: 32154671 Free PMC article.